Corresponding Author: Adam S. Cifu, MD, University of Chicago, 5841 S Maryland Ave, MC 3051, Chicago, IL 60637 (email@example.com).
Published Online: September 15, 2022. doi:10.1001/jama.2022.16667
Correction: This article was corrected on January 17, 2023, to fix an incorrect term.
Conflict of Interest Disclosures: Dr Pinney reported receipt of personal fees from Abbott, CareDx, Medtronic, TransMedics, Valgen Medtech, Ancora Heart, and ADS and nonfinancial support from Procyrion. No other disclosures were reported.
M , Anker
SD , Butler
et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med
. 2020;383(15):1413-1424. PubMedGoogle ScholarCrossref
BP , Wassall
R , Lota
et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF). Lancet
. 2019;393(10166):61-73. PubMedGoogle ScholarCrossref
VN , Murray
E , Butler
et al. In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol
. 2021;78(20):2004-2012. PubMedGoogle ScholarCrossref